Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus ZIPSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus ZIPSOR.
CHILDREN'S IBUPROFEN vs ZIPSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis involved in inflammation, pain, and fever. It has no significant inhibition of COX-1 at therapeutic doses.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
50 mg orally three times daily
None Documented
None Documented
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
2-4 hours (terminal); clinical context: short half-life necessitates frequent dosing for sustained relief; prolonged in hepatic impairment
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; remainder as glucuronide conjugates
Category D/X
Category C
NSAID
NSAID